- Home
- REXR vs ELAN Comparison
REXR vs ELAN Comparison
Compare REXR & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REXR
- ELAN
- Stock Information
- Founded
- REXR 2013
- ELAN 1954
- Country
- REXR United States
- ELAN United States
- Employees
- REXR N/A
- ELAN N/A
- Industry
- REXR Real Estate Investment Trusts
- ELAN Biotechnology: Pharmaceutical Preparations
- Sector
- REXR Real Estate
- ELAN Health Care
- Exchange
- REXR Nasdaq
- ELAN Nasdaq
- Market Cap
- REXR 8.6B
- ELAN 7.2B
- IPO Year
- REXR 2013
- ELAN 2018
- Fundamental
- Price
- REXR $40.43
- ELAN $17.91
- Analyst Decision
- REXR Hold
- ELAN Buy
- Analyst Count
- REXR 9
- ELAN 7
- Target Price
- REXR $40.00
- ELAN $17.33
- AVG Volume (30 Days)
- REXR 2.0M
- ELAN 6.7M
- Earning Date
- REXR 10-15-2025
- ELAN 08-07-2025
- Dividend Yield
- REXR 4.26%
- ELAN N/A
- EPS Growth
- REXR 11.21
- ELAN N/A
- EPS
- REXR 1.35
- ELAN 0.88
- Revenue
- REXR $986,532,000.00
- ELAN $4,484,000,000.00
- Revenue This Year
- REXR $9.25
- ELAN $4.44
- Revenue Next Year
- REXR $6.55
- ELAN $4.79
- P/E Ratio
- REXR $30.00
- ELAN $20.40
- Revenue Growth
- REXR 13.72
- ELAN N/A
- 52 Week Low
- REXR $29.68
- ELAN $8.02
- 52 Week High
- REXR $52.61
- ELAN $18.09
- Technical
- Relative Strength Index (RSI)
- REXR 68.99
- ELAN 72.60
- Support Level
- REXR $38.81
- ELAN $17.33
- Resistance Level
- REXR $39.86
- ELAN $18.09
- Average True Range (ATR)
- REXR 0.78
- ELAN 0.48
- MACD
- REXR 0.31
- ELAN 0.11
- Stochastic Oscillator
- REXR 94.59
- ELAN 95.84
About REXR Rexford Industrial Realty Inc.
Rexford Industrial Realty Inc is a real estate investment trust engaged in owning, operating, and acquiring industrial properties in Southern California infill markets. The goal is to generate attractive risk-adjusted returns for stockholders by providing superior access to industrial property investments in Southern California infill markets. It has one operating segment business of investing in, operating, and repositioning/redeveloping industrial real estate properties located in Southern California infill markets.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.